GLP-1 Companions, Explained: The 2026 Field Guide
What glp-1 companions covers, why it matters in 2026, and the numbers decision-makers should know.
Behind many of this year's biggest health tech headlines sits glp-1 companions. The digital wraparound economy growing alongside GLP-1 medications. This explainer sets out what the category actually covers, why it has moved to the center of digital therapeutics strategy, and the numbers every decision-maker should have at hand.
What it covers
The digital wraparound economy growing alongside GLP-1 medications. In practice, that spans the vendors building the technology, the health systems and payers deploying it, and the regulators writing the rules around it. The category sits inside our broader Digital Therapeutics coverage, and its daily developments stream into the live GLP-1 Companions feed.
Why it matters in 2026
Consider the current numbers: there are 192 FDA-cleared digital therapeutics devices, but only seven are currently eligible for Medicare DMHT payment.
Meanwhile, medicare DMHT patient billing grew from 99 patients in Q1 2025 to 446 by Q3 (our coverage).
Meanwhile, boehringer Ingelheim put $50 million into Click Therapeutics to commercialize its schizophrenia DTx (our coverage).
What to watch next
Three signals will tell you where glp-1 companions goes from here: the reimbursement decisions now moving through CMS and commercial payers, the consolidation pattern as larger platforms absorb point solutions, and the evidence base - peer-reviewed results increasingly separate durable categories from demo-ware.
The bottom line
Watch the regulatory calendar: the rules being written this year will shape this market for the rest of the decade. For the latest developments, follow our continuously updated GLP-1 Companions topic page.